Greenwich LifeSciences (GLSI) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Greenwich LifeSciences (GLSI) over the past year, gaining 129.0% versus a gain of 37.0%. Over five years, GLSI leads with a -59.5% price change compared with -93.4% for IPSC. Century Therapeutics is the larger company by market cap ($231.8 million vs $225.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | IPSC |
|---|---|---|
| Share price | $15.39 | $1.28 |
| Market cap | $225.90M | $231.78M |
| 1-day change | -2.53% | -3.03% |
| YTD return | -26.75% | +28.64% |
| 1-year return | +37.04% | +128.98% |
| 5-year return | -59.46% | -93.37% |
| EPS (TTM) | $-1.49 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $3.04 |
| 52-week low | $7.78 | $0.435 |
| Distance from 52-week high | -54.87% | -57.89% |
| Analyst consensus | none | buy |
| Avg. price target upside | +270.37% | +271.09% |
| Average volume | 138.58K | 658.60K |
| Shares outstanding | 14.68M | 181.08M |
| Employees | — | 78 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed GLSI by 91.9 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Healthcare · Biotechnology
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Healthcare · Biotechnology · 78 employees
GLSI vs IPSC FAQ
Which is bigger, Greenwich LifeSciences or Century Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $231.78M compared with $225.90M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or IPSC?
IPSC returned +128.98% over the past 12 months, compared with +37.04% for GLSI (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.